Protein Degradation in Focus Symposium

Therapeutic Development I, Session Chair: Alessio Ciulli
Large Lecture Theatre, Medical Sciences Institute, School of Life Sciences

Speakers

• 10.15 – 11.00 - Craig Crews Yale University, USA (Keynote),
  Tik-TAC-Toe: A Heterobifunctional for Every Need
• 11.00 – 11.20 - Mikihiko Naito, University of Tokyo, Japan
  Protein degradation induced by IAP-based PROTACs (SNIPERs)
• 11.20 – 11.40 - Ben Ebert, Dana-Farber Cancer Institute, USA
  Targeted protein degradation for the modulation of transcription
• 11.40 – 12.00 - Shaomeng Wang, University of Michigan, USA
  Targeting undruggable proteins through degradation

Discovery Chemistry & Design I, Session Chair: Dafydd Owen
Large Lecture Theatre, Medical Sciences Institute, School of Life Sciences

Speakers

• 14.00 – 14.20 - Dan Nomura, University of California, Berkeley, USA
  Reimagining Druggability using Chemoproteomic Platforms
• 14.20 – 14.40 - Fleur Ferguson, University of California, San Diego, USA
  Interrogating the Druggable Proteome with Proximity Pharmacology
• 14.40 – 15.00 - William Farnaby, University of Dundee, UK
  Pursuing targeted protein degradation for investigating CNS disease
• 15.00 – 15.15 - Laura Serini, University Medical Center Utrecht, The Netherlands
  Short Talk: A predictive screening platform for targeted degradation of cell surface proteins using SureTACs
• 15.15 – 15.30 - Matthias Hinterndorfer, Research Center for Molecular Medicine (CeMM), Austria
  Short Talk: Targeted protein degradation via intramolecular bivalent glues
• 15.30 – 15.45 - Katherine McPhie,The Francis Crick Institute, UK
  Short Talk: Chemical Biology Approaches to Explore the Ligandability of TRIM E3 Ligases

Molecular Mechanisms & Biology I, Session Chair: Ian Churcher
Large Lecture Theatre, Medical Sciences Institute, School of Life Sciences

Speakers

• 16.30 – 16.50 - Yifat Merbl, The Weizmann Institute of Science, Israel
  Proteasome Profiling: global views of protein degradation
• 16.50 – 17.10 - Ronald Hay, University of Dundee, UK
  Targeted degradation of the Promyelocytic Leukaemia protein by arsenic
• 17.10 – 17.30 - Keriann Backus, University of California, Los Angeles, USA
  Chemoproteogenomic approaches to stratify the functional and therapeutically relevant proteome
• 17.30 – 17.45 - Martin Volker Schmiedel, Boehringer Ingelheim, Austria
  Short Talk: Homo-BacPROTAC-induced degradation of ClpC1 as a strategy against drug resistant mycobacteria
• 17.45 – 18.00 - Ella Livnah, Weizmann Institute of Science, Israel
  Short Talk: Rationally designed bifunctional ligands induce intracellular precipitation of homomeric protein targets
• 18.00 – 18.15 - Alejandro Rojas-Fernandez, Universidad Austral de Chile, Chile
  Short Talk: Specific proteolysis mediated by a p97-directed proteolysis-targeting chimera (PROTAC)

Molecular Mechanisms & Biology II, Session Chair: Craig Crews
Large Lecture Theatre, Medical Sciences Institute, School of Life Sciences

Speakers

• 09.30 – 10.10 - Brenda Schulman Max Planck Institute of Biochemistry, Germany (Keynote),
  Signaling through the ubiquitin-proteasome system
• 10.10 – 10.30 - Eric Fischer, Dana-Farber Cancer Institute & Harvard Medical School, USA
  Lessons from protein design and directed evolution for degrader discovery
• 10.30 – 10.50 - Bekky Feltham, The Walter and Eliza Hall Institute for Medical Research, Australia
  Unlocking the Potential of Tag-targeting PROTACs: In Vivo Discoveries and Novel Perspectives on
  Substrate Ubiquitination

Buffet Lunch served (Poster Session II continues)

Atrium, Wellcome Trust Building, School of Life Sciences

Discovery Chemistry & Design II, Session Chair: Kirsten McAulay
Large Lecture Theatre, Medical Sciences Institute, School of Life Sciences

Speakers

• 14.00– 14.20 - Ivan Đikić, Goethe University Frankfurt and Max Planck Institute for Biophysics, Germany
  Identification of novel molecular glue degraders
• 14.20– 14.40 - Christina Woo, Harvard University, USA
  Chemical biology studies of the thalidomide-binding domain of cereblon
• 14.40– 15.00 - Michael Erb, Scripps Research, USA
  Systematic remodeling of protein-ligand surfaces for the prospective discovery of molecular glues
• 15.00– 15.15 - Johanna Huchting, Fraunhofer Institute for Translation Medicine and Pharmacology, Germany
  Short Talk: Integrated screening and knowledge platform for molecular degrader discovery
• 15.15– 15.30 - Mikołaj Słabicki, Dana-Farber Cancer Institute, USA
  Short Talk: Expanding the human zinc finger degrome targeted by glutarimide analogs through
  CRBN

Molecular Mechanisms & Biology III, Session Chair: Hannah Maple
Large Lecture Theatre, Medical Sciences Institute, School of Life Sciences

Speakers

• 16.15 – 16.35 - Georg Winter, Research Center for Molecular Medicine (CeMM), Austria
  Identification and characterization of small-molecule degraders
• 16.35 – 16.55 - Nicolas Thomä, Swiss Federal Institute of Technology (EPFL), Switzerland
  The wonderful (and mysterious) world of molecular glues
• 16.55 – 17.15 - Gopal Sapkota, University of Dundee, UK
  Targeted dephosphorylation of phospho-proteins through induced-proximity
• 17.15 – 17.30 - Charlotte Crowe, University of Dundee, UK 
  Short Talk: Mechanism of degrader-targeted protein ubiquitinability
• 17.30 – 17.45 - Jiho Park, Dana-Farber Cancer Institute, USA
  Short Talk: Polymerization of ZBTB transcription factors regulates chromatin occupancy
• 17.45 – 18.00 - David Nie, University of Toronto, Canada
  Short Talk: Recruitment of FBXO22 for Targeted Degradation of NSD2

Breakfast Social in association with the Women in TPD Network (registration only)

Mezzanine breakout area, School of Life Sciences

Discovery Chemistry & Design III, Session Chair: Brenda Schulman
Large Lecture Theatre, Medical Sciences Institute, School of Life Sciences

Speakers

• 09.30 – 10.10 - Alessio Ciulli (Keynote), University of Dundee, UK (Keynote)
  We keep degrading! CeTPD’s past, present and future
• 10.10 – 10.30 - Cristina Mayor-Ruiz, IRB Barcelona, Spain
  Degraders: unlocking drug discoveries and navigating resistance challenges
• 10.30 – 10.50 - Stefan Knapp, Goethe University and SGC Frankfurt, Germany
  Development and validation of PROTACs and E3 ligase ligands as selective chemical tools

Therapeutic Development II,Session Chair: Valentina Spiteri
Large Lecture Theatre, Medical Sciences Institute, School of Life Sciences

Speakers

• 14.00 – 14.20 Ingrid Wertz, Lyterian Therapeutics, USA
  Co-opting the Ubiquitin System for Therapeutic Benefit
• 14.20 – 14.40 - Danette Daniels, Foghorn Therapeutics, USA 
  Targeting chromatin regulatory proteins and disease with therapeutic degraders
• 14.40 – 15.00 - Angela Cacace, Arvinas, USA
  Advancements in PROTAC technology:  breaking down barriers in Neuroscience targeted drug development
• 15.00 – 15.15 - Andrea Testa, Amphista Therapeutics, UK
  Short Talk: Degradation of Brd9 by a novel “targeted glue”
• 15.15 – 15.30 - Vesna Vetma, University of Dundee, UK 
  Short Talk: Targeting cancer with small molecule pan-KRAS degraders
• 15.30 – 15.45 - Rebecca Stevens, GSK, UK
  Short Talk: Direct-to-Biology for High-Throughput PROTAC Synthesis and Biological Evaluation